Pharming receives government grant to develop human lactoferrin for inflammatory bowel diseases
The goal of this program is to demonstrate safety and effectiveness of hLF as a component of functional foods for maintaining remission periods in patients with IBD. Pharming is collaborating with NIZO food research BV (Ede), the Maastricht University Medical Centre (Division of Gastroenterology-Hepatology), NUTRIM School for Nutrition, Toxicology and Metabolism (Maastricht) and TNO (Zeist). A € 400.000 subsidy was granted by FND, which is an Innovation Programme of the Dutch Ministry of Economic Affairs, executed by its agency SenterNovem. The subsidy will cover a significant portion of the costs of the early phases of the project.
As hLF has anti-infective and anti-inflammatory properties, it could provide an effective nutritional support for IBD-patients potentially preventing or delaying periods of relapse of the disease. Pharming's human lactoferrin might also be beneficial in alleviating or preventing symptoms of other chronic or acute intestinal diseases such as Irritable bowel syndrome (IBS or spastic colon) and Traveler's diarrhea.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.